About Proline-rich protein PRCC
Proline-rich protein PRCC (PRCC) is a protein
from Homo sapiens identified by UniProt accession
Q92733, 491 residues long.
MolForge cross-references it against 0 known binders and
138 disease associations.
Target properties
| Protein name | Proline-rich protein PRCC |
| UniProt accession | Q92733 |
| Gene | PRCC |
| Organism | Homo sapiens |
| Length | 491 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (138)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.52
- renal carcinoma · score 0.37
- papillary renal cell carcinoma · score 0.21
- hepatocellular carcinoma · score 0.20
- Renal Cell Carcinoma Associated with Xp11.2 Translocations/TFE3 Gene Fusions · score 0.20
- PEComa · score 0.19
- melanoma · score 0.19
- kidney neoplasm · score 0.19
- head and neck squamous cell carcinoma · score 0.19
- acute myeloid leukemia · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q92733-F1 | alphafold | PREDICTED | 59.14 | — |
Amino-acid sequence (491 residues)
MSLVAYASSD ESEPDEAEPE PEEEEAVAPT SGPALGGLFA SLPAPKGPAL LPPPPQMLAP AFPPPLLLPP PTGDPRLQPP PPLPFGLGGF PPPPGVSPAE AAGVGEGLGL GLPSPRGPGL NLPPPIGGAG PPLGLPKPKK RKEPVKIAAP ELHKGDSDSE EDEPTKKKTI LQGSSEGTGL SALLPQPKNL TVKETNRLLL PHAFSRKPSD GSPDTKPSRL ASKTKTSSLA PVVGTTTTTP SPSAIKAAAK SAALQVTKQI TQEEDDSDEE VAPENFFSLP EKAEPPGVEP YPYPIPTVPE ELPPGTEPEP AFQDDAANAP LEFKMAAGSS GAPWMPKPGD DYSYNQFSTY GDANAAGAYY QDYYSGGYYP AQDPALVPPQ EIAPDASFID DEAFKRLQGK RNRGREEINF VEIKGDDQLS GAQQWMTKSL TEEKTMKSFS KKKGEQPTGQ QRRKHQITYL IHQAKERELE LKNTWSENKL SRRQTQAKYG F
Explore Proline-rich protein PRCC with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets